Immunology
-
Broad human and animal coronavirus neutralisation by SARS-CoV-2 S2-targeted vaccination
This article has 21 authors:Reviewed by ScreenIT
-
Heteologous saRNA-Prime, DNA Dual-Antigen-Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies
This article has 17 authors:Reviewed by ScreenIT
-
SARS-CoV-2–specific T cells in unexposed adults display broad trafficking potential and cross-react with commensal antigens
This article has 12 authors:Reviewed by ScreenIT
-
COVID-19 lung disease shares driver AT2 cytopathic features with Idiopathic pulmonary fibrosis
This article has 10 authors:Reviewed by ScreenIT
-
A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD
This article has 29 authors:Reviewed by ScreenIT
-
A recombinant SARS-CoV-2 RBD antigen expressed in insect cells elicits immunogenicity and confirms safety in animal models
This article has 23 authors:Reviewed by ScreenIT
-
A large-scale systematic survey of SARS-CoV-2 antibodies reveals recurring molecular features
This article has 5 authors:Reviewed by ScreenIT
-
Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model
This article has 26 authors:Reviewed by ScreenIT
-
Distinct SARS-CoV-2 sensing pathways in pDCs driving TLR7-antiviral vs. TLR2-immunopathological responses in COVID-19
This article has 26 authors:Reviewed by ScreenIT
-
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2
This article has 46 authors:Reviewed by ScreenIT